Publié dans European Heart Journal Cardiovascular Pharmacotherapy 2020 Jul 11 :pvaa077

Auteurs : Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet JP, Bruckert E, Montalescot G.

Article disponible en consultant le site


European Heart Journal - Cardiovascular Pharmacotherapy

In 2019, the European Society of Cardiology and European Atherosclerosis Society released a new guideline document with substantial changes regarding the assessment of cardiovascular risk and treatments. The update of high-risk criteria and categories led to a better detection and primary prevention of patients at risk of a first cardiovascular event. Nonetheless, additional efforts are needed for a better inclusion of risk modifiers, especially specific to women, to improve risk stratification and direct primary prevention. Eventually, we discuss how these new guidelines implement PCSK9 inhibitors for very-high risk individuals and the evidence supporting new LDL-C goals below such as 55 mg/dL and 40 mg/dL. […]